Brief: LumiraDx Receives CE Mark For Two Multiplex Tests
08/06/2022 11:20
June 8 (Reuters) - LumiraDx Ltd LMDX.O :
* LUMIRADX RECEIVES CE MARK FOR TWO MULTIPLEX TESTS:
LUMIRADX
DUAL-TARGET SARS-COV-2 STAR COMPLETE AND LUMIRADX SARS-COV-2 &
FLU A/B RNA STAR COMPLETE
Source text for Eikon: ID:nPn1qSCxVa
Further company coverage: LMDX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on LumiraDx
See all newsBrief: LumiraDx Announces Its Securities Will Be Suspended From Trading On Nasdaq At The Open Of Business On January 9Th
Roche to buy part of LumiraDx diagnostics platform for $295 million
Brief: LumiraDx- Under Terms Of Certain Loan Agreement, Dated March 23, 2021, The Waiver Period Has Expired As Of Today
Brief: LumiraDx Announces Agreement to Sell its Cutting Edge Point of Care Technology Platform to Roche
Brief: Willard L. Umphrey Reports 10.31% Stake In Lumiradx Limited As Of Dec 22- SEC Filing